COMMUNITY pharmacies are being invited to participate in a new Teva Wake Patient Program conducted in partnership with PharmaPrograms, providing opportunities for additional professional services income.
The initiative relates to Modafinil and Nuvigil (armodafinil) and consists of two distinct elements.
The new Modafinil Patient Screening Program involves the pharmacist undertaking a short patient interview including the completion of a tailored Screening Questionnaire which reviews medication compliance.
This part of the program is a one-off service with a professional fee paid to the community pharmacy.
Under the Nuvigil Patient Program, the pharmacist is required to complete a tailored Patient Information Leaflet containing key QUM issues which are to be discussed with the patient.
The community pharmacy will be paid a continued professional service fee at each dispensing under the Nuvigil scheme.
The medications are indicated to improve wakefulness in people with excessive daytime sleepiness.
The new Teva program is the 14th PharmaPrograms initiative through community pharmacy, in partnership with 11 manufacturers.
For more details call 1300 721 225 or see pharmaprograms.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Sep 18